Abstract
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in adult males. Although prostate cancer that is confined to the gland can be cured in many patients using surgery or radiation, these treatments are only effective for localized tumors and the long-term failure rates for these treatments suggests that prostate cancer can metastasize relatively early in the course of the disease. Once prostate cancer has metastasized there are no curative therapies. The greatest challenge in the treatment of advanced prostate cancer is to access and eliminate metastatic cells. Therefore, effective prostate cancer therapy will require novel strategies to target cancer cells both at the site of the primary tumor and at distant metastatic sites. In this article we review several therapeutic targets and approaches that may provide new treatments for metastatic prostate cancer. We discuss the use of small molecules to target specific molecular events associated with metastatic prostate cancer, the use of specific antibodies that target unique metastasis associated molecules and the use of various gene therapy strategies to achieve anti-metastatic activities.
Keywords: gene therapy, Immunotherapy, antibody therapy, rtvp, caveolin, interleukin-12
Current Drug Targets
Title: Therapeutic Targets for Metastatic Prostate Cancer
Volume: 4 Issue: 3
Author(s): Terry L. Timme, Takefumi Satoh, Salahaldin A. Tahir, Hongyu Wang, Bin S. The, E. Brian Butler, Brian J. Miles, Robert J. Amato, Dov Kadmon and Timothy C. Thompson
Affiliation:
Keywords: gene therapy, Immunotherapy, antibody therapy, rtvp, caveolin, interleukin-12
Abstract: Prostate cancer is the most commonly diagnosed non-cutaneous cancer in adult males. Although prostate cancer that is confined to the gland can be cured in many patients using surgery or radiation, these treatments are only effective for localized tumors and the long-term failure rates for these treatments suggests that prostate cancer can metastasize relatively early in the course of the disease. Once prostate cancer has metastasized there are no curative therapies. The greatest challenge in the treatment of advanced prostate cancer is to access and eliminate metastatic cells. Therefore, effective prostate cancer therapy will require novel strategies to target cancer cells both at the site of the primary tumor and at distant metastatic sites. In this article we review several therapeutic targets and approaches that may provide new treatments for metastatic prostate cancer. We discuss the use of small molecules to target specific molecular events associated with metastatic prostate cancer, the use of specific antibodies that target unique metastasis associated molecules and the use of various gene therapy strategies to achieve anti-metastatic activities.
Export Options
About this article
Cite this article as:
Timme L. Terry, Satoh Takefumi, Tahir A. Salahaldin, Wang Hongyu, The S. Bin, Butler Brian E., Miles J. Brian, Amato J. Robert, Kadmon Dov and Thompson C. Timothy, Therapeutic Targets for Metastatic Prostate Cancer, Current Drug Targets 2003; 4 (3) . https://dx.doi.org/10.2174/1389450033491127
DOI https://dx.doi.org/10.2174/1389450033491127 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Cholinergic Targets in Lung Cancer
Current Pharmaceutical Design The Implication of Platelet Activating Factor in Cancer Growth and Metastasis: Potent Beneficial Role of PAF-Inhibitors and Antioxidants
Infectious Disorders - Drug Targets Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors
Mini-Reviews in Medicinal Chemistry Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design MicroRNAs: Modulators of Tooth Development
MicroRNA Immunoprevention of Pancreatic Cancer
Current Medicinal Chemistry Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Polymorphism of UDP-Glucuronosyltransferase and Drug Metabolism
Current Drug Metabolism Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Seq and You Will Find
Current Gene Therapy Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Avocado (Persea americana) Seed as a Source of Bioactive Phytochemicals
Current Pharmaceutical Design BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy Human Complex Trait Genetics: Lifting the Lid of the Genomics Toolbox - from Pathways to Prediction
Current Genomics